Mechanism-based corrector combination restores ΔF508-CFTR folding and function

Nature Chemical Biology

Volumn 9, Issue 7, 2013, Pages 444-454

  Okiyoneda, Tsukasa ^a,i   Veit, Guido ^a   Dekkers, Johanna F ^b,c   Bagdany, Miklos ^a   Soya, Naoto ^a   Xu, Haijin ^a   Roldan, Ariel ^a   Verkman, Alan S ^d,e   Kurth, Mark ^f   Simon, Agnes ^g   Hegedus, Tamas ^g,h   Beekman, Jeffrey M ^b,c   Lukacs, Gergely L ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Department of Pediatric Pulmonology   (Canada)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^h SEMMELWEIS UNIVERSITY   (Hungary)

ⁱ KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LUMACAFTOR; MEMBRANE PROTEIN; MEMBRANE SPANNING DOMAIN 1; MEMBRANE SPANNING DOMAIN 2; NUCLEOTIDE BINDING DOMAIN 1; NUCLEOTIDE BINDING DOMAIN 2; NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOPLASM; ENERGY TRANSFER; FLUOROMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE CELL; LUNG ALVEOLUS CELL; MEMBRANE STABILIZATION; MISSENSE MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN TARGETING; WILD TYPE;

AMINOPYRIDINES; ANIMALS; BENZODIOXOLES; BINDING SITES; BRONCHI; CELL MEMBRANE; CRICETINAE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC RETICULUM; EPITHELIAL CELLS; GLYCOSYLATION; HUMANS; MUTATION; NUCLEOTIDES; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

EID: 84879410121     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1253     Document Type: Article

References (60)

1. Riordan, J.R. CFTR function and prospects for therapy. Annu. Rev. Biochem. 77, 701-726 (2008).
2. He, L. et al. Multiple membrane-cytoplasmic domain contacts in the cystic fibrosis transmembrane conductance regulator (CFTR) mediate regulation of channel gating. J. Biol. Chem. 283, 26383-26390 (2008).
3. Serohijos, A.W. et al. Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc. Natl. Acad. Sci. USA 105, 3256-3261 (2008).
4. Kim, S.J. & Skach, W.R. Mechanisms of CFTR folding at the endoplasmic reticulum. Front. Pharmacol. 3, 201 (2012).
5. Du, K., Sharma, M. & Lukacs, G.L. The ΔF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat. Struct. Mol. Biol. 12, 17-25 (2005).
6. Du, K. & Lukacs, G.L. Cooperative assembly and misfolding of CFTR domains in vivo. Mol. Biol. Cell 20, 1903-1915 (2009).
7. He, L. et al. Restoration of domain folding and interdomain assembly by second-site suppressors of the ΔF508 mutation in CFTR. FASEB J. 24, 3103-3112 (2010).
8. Cui, L. et al. Domain interdependence in the biosynthetic assembly of CFTR. J. Mol. Biol. 365, 981-994 (2007).
9. Kleizen, B., van Vlijmen, T., de Jonge, H.R. & Braakman, I. Folding of CFTR is predominantly cotranslational. Mol. Cell 20, 277-287 (2005).
10. Rosser, M.F., Grove, D.E., Chen, L. & Cyr, D.M. Assembly and misassembly of cystic fibrosis transmembrane conductance regulator: Folding defects caused by deletion of F508 occur before and after the calnexin-dependent association of membrane spanning domain (MSD) 1 and MSD2. Mol. Biol. Cell 19, 4570-4579 (2008).
11. Balch, W.E., Roth, D.M. & Hutt, D.M. Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb. Perspect. Biol. 3, a004499 (2011).
12. Boucher, R.C. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur. Respir. J. 23, 146-158 (2004).
13. Veit, G. et al. Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. Mol. Biol. Cell 23, 4188-4202 (2012).
14. Van Goor, F. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci. USA 108, 18843-18848 (2011).
15. Denning, G.M. et al. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358, 761-764 (1992).
16. Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J. & Kopito, R.R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271, 635-638 (1996).
17. Pedemonte, N. et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J. Clin. Invest. 115, 2564-2571 (2005).
18. Varga, K. et al. Enhanced cell-surface stability of rescued ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) by pharmacological chaperones. Biochem. J. 410, 555-564 (2008).
19. Hanrahan, J.W., Sampson, H.M. & Thomas, D.Y. Novel pharmacological strategies to treat cystic fibrosis. Trends Pharmacol. Sci. 34, 119-125 (2013).
20. Van Goor, F. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc. Natl. Acad. Sci. USA 106, 18825-18830 (2009).
21. Clancy, J.P. et al. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax 67, 12-18 (2012).
22. Sampson, H.M. et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem. Biol. 18, 231-242 (2011).
23. Howard, M. et al. Mammalian osmolytes and S-nitrosoglutathione promote ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J. Biol. Chem. 278, 35159-35167 (2003).
24. Kim Chiaw, P., Wellhauser, L., Huan, L.J., Ramjeesingh, M. & Bear, C.E. A chemical corrector modifies the channel function of F508del-CFTR. Mol. Pharmacol. 78, 411-418 (2010).
25. Protasevich, I. et al. Thermal unfolding studies show the disease causing F508del mutation in CFTR thermodynamically destabilizes nucleotide-binding domain 1. Protein Sci. 19, 1917-1931 (2010).
26. Wang, C. et al. Integrated biophysical studies implicate partial unfolding of NBD1 of CFTR in the molecular pathogenesis of F508del cystic fibrosis. Protein Sci. 19, 1932-1947 (2010).
27. Rabeh, W.M. et al. Correction of both NBD1 energetics and domain interface is required to restore ΔF508 CFTR folding and function. Cell 148, 150-163 (2012).
28. Mendoza, J.L. et al. Requirements for efficient correction of ΔF508 CFTR revealed by analyses of evolved sequences. Cell 148, 164-174 (2012).
29. Robert, R. et al. Correction of the Δphe508 cystic fibrosis transmembrane conductance regulator trafficking defect by the bioavailable compound glafenine. Mol. Pharmacol. 77, 922-930 (2010).
30. Loo, T.W., Bartlett, M.C. & Clarke, D.M. The V510D suppressor mutation stabilizes ΔF508-CFTR at the cell surface. Biochemistry 49, 6352-6357 (2010).
31. Teem, J.L. et al. Identification of revertants for the cystic fibrosis ΔF508 mutation using STE6-CFTR chimeras in yeast. Cell 73, 335-346 (1993).
32. Pedemonte, N. et al. Dual activity of aminoarylthiazoles on the trafficking and gating defects of the cystic fibrosis transmembrane conductance regulator chloride channel caused by cystic fibrosis mutations. J. Biol. Chem. 286, 15215-15226 (2011).
33. Phuan, P.W. et al. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis. Mol. Pharmacol. 80, 683-693 (2011).
34. Hegedus, T. et al. F508del CFTR with two altered RXR motifs escapes from ER quality control but its channel activity is thermally sensitive. Biochim. Biophys. Acta 1758, 565-572 (2006).
35. Aleksandrov, A.A. et al. Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. J. Mol. Biol. 419, 41-60 (2012).
36. Dalton, J., Kalid, O., Schushan, M., Ben-Tal, N. & Villa-Freixa, J. New model of cystic fibrosis transmembrane conductance regulator proposes active channel-like conformation. J. Chem. Inf. Model. 52, 1842-1853 (2012).
37. Kalid, O. et al. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J. Comput. Aided Mol. Des. 24, 971-991 (2010).
38. He, L. et al. Correctors of ΔF508 CFTR restore global conformational maturation without thermally stabilizing the mutant protein. FASEB J. 27, 536-545 (2013).
39. Thibodeau, P.H. et al. The cystic fibrosis-causing mutation ΔF508 affects multiple steps in cystic fibrosis transmembrane conductance regulator biogenesis. J. Biol. Chem. 285, 35825-35835 (2010).
40. Grove, D.E., Rosser, M.F., Ren, H.Y., Naren, A.P. & Cyr, D.M. Mechanisms for rescue of correctable folding defects in CFTRΔF508. Mol. Biol. Cell 20, 4059-4069 (2009).
41. Zhang, F., Kartner, N. & Lukacs, G.L. Limited proteolysis as a probe for arrested conformational maturation of ΔF508 CFTR. Nat. Struct. Biol. 5, 180-183 (1998).
42. Yu, G.J. et al. Potent S-cis-locked bithiazole correctors of ΔF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J. Med. Chem. 51, 6044-6054 (2008).
43. Aleksandrov, A.A. et al. Regulatory insertion removal restores maturation, stability and function of ΔF508 CFTR. J. Mol. Biol. 401, 194-210 (2010).
44. Lewis, H.A. et al. Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry. J. Mol. Biol. 396, 406-430 (2010).
45. Dekkers, J. et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat. Med. (in the press).
46. Zhang, X.M. et al. Organic solutes rescue the functional defect in ΔF508 cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 278, 51232-51242 (2003).
47. Wang, Y., Loo, T.W., Bartlett, M.C. & Clarke, D.M. Additive effect of multiple pharmacological chaperones on maturation of CFTR processing mutants. Biochem. J. 406, 257-263 (2007).
48. Pedemonte, N., Tomati, V., Sondo, E. & Galietta, L.J. Influence of cell background on pharmacological rescue of mutant CFTR. Am. J. Physiol. Cell Physiol. 298, C866-C874 (2010).
49. Liu, X., O'Donnell, N., Landstrom, A., Skach, W.R. & Dawson, D.C. Thermal instability of ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) channel function: Protection by single suppressor mutations and inhibiting channel activity. Biochemistry 51, 5113-5124 (2012).
50. Wellhauser, L. et al. A small-molecule modulator interacts directly with ΔPhe508-CFTR to modify its ATPase activity and conformational stability. Mol. Pharmacol. 75, 1430-1438 (2009).
51. Eckford, P.D., Li, C., Ramjeesingh, M. & Bear, C.E. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (Ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287, 36639-36649 (2012).
52. Okiyoneda, T. et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329, 805-810 (2010).
53. Glasoe, P.K. & Long, F.A. Use of glass electrodes to measure acidities in deuterium oxide. J. Phys. Chem. 64, 188-190 (1960).
54. Wales, T.E. & Engen, J.R. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom. Rev. 25, 158-170 (2006).
55. Cornell, W.D. et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117, 5179-5197 (1995).
56. Wang, J., Cieplak, P. & Kollmann, P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? J. Comput. Chem. 21, 1049-1074 (2000).
57. Fiser, A. & Sali, A. ModLoop: Automated modeling of loops in protein structures. Bioinformatics 19, 2500-2501 (2003).
58. Schüttelkopf, A.W. & van Aalten, D.M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr. D Biol. Crystallogr. 60, 1355-1363 (2004).
59. Morris, G.M. et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30, 2785-2791 (2009).
60. Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology 141, 1762-1772 (2011).